Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02479386 · ClinicalTrials.gov registry record
A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A clinical trial, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- 296
- Enrollment target
NCT02479386: Clinical Trial study, sponsored by Hoffmann-La Roche.
NCT02479386 is a clinical trial that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 296 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02479386 was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- 296 participants
- Enrollment target
Study Summary
This study seeks to better characterize relationships between visual function and the progression (worsening) of geographic atrophy (GA) due to age-related macular degeneration (AMD). The study is also intended to generate new information on the relationship between genetics and GA progression. This is a global, prospective, multicenter, epidemiologic study enrolling participants with GA secondary to AMD. The study visits are scheduled to occur every 6 months. The anticipated duration of the study is up to 48 months. There is a planned interim analysis around the 2-year time window for the study.
Interventions
- OTHER No intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 296 participants |
| Start Date | 2015-06-24 |
| Est. Completion | 2018-01-31 |
Why NCT02479386 stopped before completion
NCT02479386 is an observational study that tracks outcomes without assigning an intervention. The registered 296 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which No intervention is the first listed.
NCT02479386 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02479386 about?
NCT02479386 is a clinical study titled "A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration". This study seeks to better characterize relationships between visual function and the progression (worsening) of geographic atrophy (GA) due to age-related macular degeneration (AMD). The study is also intended to generate new information on the relationship between genetics and GA progression. This...
What is the current status of trial NCT02479386?
This trial is currently terminated. The enrollment target is 296 participants. The study started on 2015-06-24. Estimated completion is 2018-01-31.
What interventions are being tested in trial NCT02479386?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT02479386?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05563792 · 296 participants · NA
Options for Pain Management Using Nonpharmacological Strategies
- NCT06828445 · 296 participants · Phase 1
Increasing Affordable Fruits and Vegetables for Families With Food Insecurity
- NCT06920563 · 296 participants · NA
Remote Postpartum Blood Pressure Monitoring and Cardiovascular Education
- NCT06309160 · 297 participants · NA
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI